{"success":true,"data":{"pressRelease":{"id":"164770","rtpr_id":"nGNXbTxVC6-20261008","ticker":"XRTX","exchange":"NASDAQ","all_tickers":["XRTX"],"title":"XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout","author":"Globe Newswire","published_at":"2026-10-08T20:00:00.166Z","article_body":"● Clinical Trial Application planned for filing with Health Canada,\nextending the Company’s international regulatory strategy for gout program\nXRx-026 ●\n\nCALGARY, Alberta, Oct. 08, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc.\n(“XORTX” or the “Company”) (NASDAQ: XRTX), a late-stage clinical\npharmaceutical company focused on developing innovative therapies to treat\ngout and progressive kidney disease, is pleased to provide an outline of its\nanticipated Clinical Trial Application (“CTA”) submission to Health Canada\nfor the XRx-026 gout program. The filing supports the Company’s planned\ntwo-part clinical study, XRX-OXY-102, evaluating XORLO(TM), the Company’s\nproprietary formulation of oxypurinol, a xanthine oxidase inhibitor, for the\ntreatment of gout. Conducting the first part of the XRX-OXY-102 clinical study\nin Canada is expected to enable the Company to accelerate the delivery of key\nclinical data in support of its planned New Drug Application (“NDA”)\nfiling with the U.S. Food and Drug Administration (the “FDA”) for\nmarketing approval.\n\nRecent drug development team activities have included parallel preparation of\nthe CTA for filing with Health Canada. The application describes the\nCompany’s clinical development plan for XRx-026 and its intention to advance\nthe program toward regulatory approval in Canada in parallel with its planned\nNDA filing with the FDA. Part one of the XRX-OXY-102 clinical trial builds\nupon the previously reported positive clinical results for the proprietary\nXORLO™ formulation and extends characterization of the commercial tablet\nform.\n\n“Advancing our Clinical Trial Application with Health Canada is expected to\nenable more efficient clinical plan execution and extends our regulatory\nstrategy for XRx-026 globally,” said Dr. Allen Davidoff, Co-Chief Executive\nOfficer of XORTX, who added, “Gout is a growing global burden, and\napproaches that make more efficient use of our capital, personnel and time are\nexpected to accelerate the availability of XORLO™ to patients wherever the\nneed exists. This, in turn, is anticipated to enhance the overall value of the\nXRx-026 program for the Company and its shareholders.”\n\nAs the XRx-026 program has advanced, the Company has received increased\ninquiries from potential commercialization partners in a number of\njurisdictions. The Company has not entered into any agreement with any such\nparty, and there can be no assurance that any of these discussions will result\nin a transaction. XORTX looks forward to providing further updates regarding\nthe XRx-026 drug development program as it advances toward the planned CTA and\nNDA filings.\n\nAbout Hyperuricemia and Gout\n\nIn the United States, approximately 44 million individuals have uric acid\nlevels above the normal range, with 9.2 million individuals living with\ngout(1). Gout is associated with severe pain, reduced quality of life(2),\ndecreased physical function(3), increased healthcare costs(4), and lost\neconomic productivity(5). It is also strongly associated with metabolic\nsyndrome(5), myocardial infarction(6,7), Type 2 diabetes mellitus(8), chronic\nkidney disease(9), and premature mortality(6,10,11). Importantly, the global\nprevalence of gout is increasing, with cases expected to increase 70% over the\nnext 25 years(*).\n\n* https://pubmed.ncbi.nlm.nih.gov/38996590/\n\nAbout the XRx-026 Program and XORLO™\n\nThe XRx-026 program is developing XORLO™, the Company’s proprietary\nformulation of oxypurinol, to treat individuals with gout. Oral xanthine\noxidase inhibitors (“XOIs”) are the current standard of care for treating\nhyperuricemia-associated gout. Allopurinol is the recommended first-line\ntherapy for gout; however, limitations remain: approximately 3–5% of\npatients cannot tolerate allopurinol. An alternative XOI, febuxostat, at one\ntime achieved annual peak net sales >US$450 million, and now carries a boxed\nwarning for cardiovascular risk which has substantially decreased its use and\nsales. XORLO™ is designed to address this unmet need by providing an\nalternative therapeutic option with a differentiated safety and efficacy\nprofile. Advancement of XRx-026 through the planned CTA and NDA filings is a\nstrategic priority for XORTX.\n\nReferences\n1. Chen-Xu M, et al. Prevalence of Gout and Hyperuricemia in the US. Arthritis\nRheumatol. 2019;71(6):991–999.\n2. Singh JA. Quality of life and quality of care for patients with gout. Curr\nRheumatol Rep. 2009;11(2):154–60.\n3. Burke BT, et al. Physical Function, Hyperuricemia, and Gout in Older\nAdults. Arthritis Care Res. 2015;67(12):1730–8.\n4. Rai SK, et al. The economic burden of gout: a systematic review. Semin\nArthritis Rheum. 2015;45(1):75–80.\n5. Choi HK, et al. Prevalence of the metabolic syndrome in individuals with\nhyperuricemia. Am J Med. 2007;120(5):442–7.\n6. Choi HK, Curhan G. Independent impact of gout on mortality and risk for\ncoronary heart disease. Circulation. 2007;116(8):894–900.\n7. Liu S-C, et al. Gout and Risk of Myocardial Infarction: A Systematic\nReview. PLoS ONE. 2015;10(7):e0134088.\n8. Choi HK, et al. Gout and the risk of type 2 diabetes among men with high\ncardiovascular risk profile. Rheumatology. 2008;47(10):1567–70.\n9. Roughley MJ, et al. Gout and risk of chronic kidney disease and\nnephrolithiasis: meta-analysis. Arthritis Res Ther. 2015;17(1).\n10. Kuo C-F, et al. Gout: an independent risk factor for all-cause and\ncardiovascular mortality. Rheumatology. 2010;49(1):141–6.\n11. Fisher MC, et al. Premature mortality gap in gout: a general\npopulation-based study. Ann Rheum Dis. 2017;76(7):1289–94.\nAbout XORTX Therapeutics Inc.\n\nXORTX is a pharmaceutical company with three clinically advanced products in\ndevelopment: 1) our lead XRx-026 program for the treatment of gout; 2) XRx-008\nprogram for ADPKD; and 3) XRx-101 for acute kidney and other acute organ\ninjury associated with respiratory virus infections. In addition, the Company\nis developing XRx-225, a pre-clinical stage program for Type 2 diabetic\nnephropathy, and the recently acquired VB4-P5 program, which is currently at\nthe pre-IND stage of development and targets both rare and prevalent forms of\nkidney disease. XORTX is working to advance products that target aberrant\npurine metabolism and xanthine oxidase to decrease or inhibit production of\nuric acid. At XORTX, we are dedicated to developing medications that improve\nthe quality of life and health of individuals with gout and other important\ndiseases.\n\nFor more information, please contact:\n\n Allen Davidoff, Co-CEO    Mika Grasso, Co-CEO  \n adavidoff@xortx.com       mgrasso@xortx.com    \n +1 403 455 7727           +1 949 244 6011      \n                                                \n\nForward-Looking Statements\n\nThis press release contains “forward-looking statements” within the\nmeaning of the safe harbor provisions of the U.S. Private Securities\nLitigation Reform Act of 1995, as well as “forward-looking information”\nwithin the meaning of applicable Canadian securities laws. Forward-looking\nstatements may be identified by the use of words such as “anticipate,”\n“believe,” “expect,” “estimate,” “plan,” “intend,”\n“will,” “designed to,” “enable,” “accelerate,” “extend,”\n“potential,” “looks forward,” and similar expressions, and include all\nstatements that are not statements of historical fact. These forward-looking\nstatements include, but are not limited to, statements regarding the\npreparation, timing, content and submission of the Company’s planned CTA to\nHealth Canada for the XRx-026 program; the design, initiation, conduct and\ncompletion of the planned two-part XRX-OXY-102 clinical study, including the\nCompany’s plan to conduct the first part of the study in Canada; the\nCompany’s expectation that conducting the first part of the study in Canada\nwill accelerate the delivery of clinical data in support of its planned NDA\nfiling with the FDA; the Company’s regulatory strategy in the United States,\nCanada and other jurisdictions, including the timing and content of its\nplanned regulatory submissions to the FDA and its intention to advance the\nXRx-026 program toward regulatory approval in Canada; the Company’s\nexpectations regarding the more efficient use of its capital, personnel and\ntime and the potential to accelerate the availability of XORLO™ to patients;\ninterest from, and the potential for arrangements with, commercialization\npartners; statements regarding the prevalence of hyperuricemia and gout and\nthe projected growth in the prevalence of gout, which are based on third-party\ndata; and the advancement of the Company’s XRx-026 program, its other\ndevelopment programs, and its strategy.\n\nForward-looking statements are based on the Company’s current expectations\nand assumptions and are subject to known and unknown risks, uncertainties, and\nother factors that could cause actual results, performance, or achievements to\ndiffer materially from those expressed or implied by such statements. Such\nrisks and uncertainties include, among others: the Company’s need for, and\nability to obtain, additional capital to fund its development programs and\noperations; the risk that the Company’s CTA submission to Health Canada is\ndelayed or, once submitted, is not accepted by Health Canada, is subject to\nobjection or to requests for additional information or data, or is otherwise\nnot permitted to proceed; the risk that the Company’s regulatory submissions\nto the FDA are delayed or not accepted, or that the planned XRX-OXY-102\nclinical study is placed on clinical hold or otherwise not permitted to\nproceed by the FDA; the Company’s ability to initiate, conduct, and complete\nthe planned XRX-OXY-102 clinical study, in Canada and elsewhere, on the\ntimelines currently anticipated, or at all, and the risk that the results of\nthat study are not positive, are not accepted by the FDA, or do not support an\nNDA submission; the risk that Health Canada or the FDA does not agree with the\nCompany’s proposed clinical development plan or regulatory pathway, or\nrequires additional studies or data; the Company’s reliance on third-party\ncontract research organizations and contract manufacturers; the risk that\ndiscussions with potential commercialization partners do not result in any\nagreement on acceptable terms, or at all; the risk that third-party data\nregarding the prevalence of hyperuricemia and gout, and projections of future\nprevalence, prove to be inaccurate; competition from existing and future\ntherapies for gout; the Company’s ability to advance, and obtain regulatory\napproval for, the XRx-026 program and its other product candidates on the\ntimelines currently anticipated, or at all; the evolving regulatory\nenvironment applicable to the Company’s business in the United States and\nCanada; the Company’s ability to maintain the listing of its common shares\non the Nasdaq Capital Market; and the Company’s ability to attract and\nretain qualified personnel.\n\nFor a more detailed discussion of these and other risks and uncertainties,\ninvestors should review the disclosures contained under the heading “Risk\nFactors” in the Company’s Annual Report on Form 20-F for the fiscal year\nended December 31, 2025, and in the Company’s subsequent Reports of Foreign\nPrivate Issuer on Form 6-K, each as filed with or furnished to the SEC and\navailable at www.sec.gov, as well as in the Company’s continuous disclosure\ndocuments filed with the Canadian securities regulatory authorities and\navailable at www.sedarplus.ca.\n\nThe forward-looking statements in this press release speak only as of the date\nhereof. Except as required by law, the Company undertakes no obligation to\nupdate or revise any forward-looking statement, whether as a result of new\ninformation, future events, or otherwise. Readers are cautioned not to place\nundue reliance on these forward-looking statements.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/9898c4f8-b373-438a-abfa-709c4372a061)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXbTxVC6-20261008","title":"XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout","author":"Globe Newswire","ticker":"XRTX","created":"2026-10-08T20:00:00.166Z","tickers":["XRTX"],"exchange":"NASDAQ","article_body":"● Clinical Trial Application planned for filing with Health Canada,\nextending the Company’s international regulatory strategy for gout program\nXRx-026 ●\n\nCALGARY, Alberta, Oct. 08, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc.\n(“XORTX” or the “Company”) (NASDAQ: XRTX), a late-stage clinical\npharmaceutical company focused on developing innovative therapies to treat\ngout and progressive kidney disease, is pleased to provide an outline of its\nanticipated Clinical Trial Application (“CTA”) submission to Health Canada\nfor the XRx-026 gout program. The filing supports the Company’s planned\ntwo-part clinical study, XRX-OXY-102, evaluating XORLO(TM), the Company’s\nproprietary formulation of oxypurinol, a xanthine oxidase inhibitor, for the\ntreatment of gout. Conducting the first part of the XRX-OXY-102 clinical study\nin Canada is expected to enable the Company to accelerate the delivery of key\nclinical data in support of its planned New Drug Application (“NDA”)\nfiling with the U.S. Food and Drug Administration (the “FDA”) for\nmarketing approval.\n\nRecent drug development team activities have included parallel preparation of\nthe CTA for filing with Health Canada. The application describes the\nCompany’s clinical development plan for XRx-026 and its intention to advance\nthe program toward regulatory approval in Canada in parallel with its planned\nNDA filing with the FDA. Part one of the XRX-OXY-102 clinical trial builds\nupon the previously reported positive clinical results for the proprietary\nXORLO™ formulation and extends characterization of the commercial tablet\nform.\n\n“Advancing our Clinical Trial Application with Health Canada is expected to\nenable more efficient clinical plan execution and extends our regulatory\nstrategy for XRx-026 globally,” said Dr. Allen Davidoff, Co-Chief Executive\nOfficer of XORTX, who added, “Gout is a growing global burden, and\napproaches that make more efficient use of our capital, personnel and time are\nexpected to accelerate the availability of XORLO™ to patients wherever the\nneed exists. This, in turn, is anticipated to enhance the overall value of the\nXRx-026 program for the Company and its shareholders.”\n\nAs the XRx-026 program has advanced, the Company has received increased\ninquiries from potential commercialization partners in a number of\njurisdictions. The Company has not entered into any agreement with any such\nparty, and there can be no assurance that any of these discussions will result\nin a transaction. XORTX looks forward to providing further updates regarding\nthe XRx-026 drug development program as it advances toward the planned CTA and\nNDA filings.\n\nAbout Hyperuricemia and Gout\n\nIn the United States, approximately 44 million individuals have uric acid\nlevels above the normal range, with 9.2 million individuals living with\ngout(1). Gout is associated with severe pain, reduced quality of life(2),\ndecreased physical function(3), increased healthcare costs(4), and lost\neconomic productivity(5). It is also strongly associated with metabolic\nsyndrome(5), myocardial infarction(6,7), Type 2 diabetes mellitus(8), chronic\nkidney disease(9), and premature mortality(6,10,11). Importantly, the global\nprevalence of gout is increasing, with cases expected to increase 70% over the\nnext 25 years(*).\n\n* https://pubmed.ncbi.nlm.nih.gov/38996590/\n\nAbout the XRx-026 Program and XORLO™\n\nThe XRx-026 program is developing XORLO™, the Company’s proprietary\nformulation of oxypurinol, to treat individuals with gout. Oral xanthine\noxidase inhibitors (“XOIs”) are the current standard of care for treating\nhyperuricemia-associated gout. Allopurinol is the recommended first-line\ntherapy for gout; however, limitations remain: approximately 3–5% of\npatients cannot tolerate allopurinol. An alternative XOI, febuxostat, at one\ntime achieved annual peak net sales >US$450 million, and now carries a boxed\nwarning for cardiovascular risk which has substantially decreased its use and\nsales. XORLO™ is designed to address this unmet need by providing an\nalternative therapeutic option with a differentiated safety and efficacy\nprofile. Advancement of XRx-026 through the planned CTA and NDA filings is a\nstrategic priority for XORTX.\n\nReferences\n1. Chen-Xu M, et al. Prevalence of Gout and Hyperuricemia in the US. Arthritis\nRheumatol. 2019;71(6):991–999.\n2. Singh JA. Quality of life and quality of care for patients with gout. Curr\nRheumatol Rep. 2009;11(2):154–60.\n3. Burke BT, et al. Physical Function, Hyperuricemia, and Gout in Older\nAdults. Arthritis Care Res. 2015;67(12):1730–8.\n4. Rai SK, et al. The economic burden of gout: a systematic review. Semin\nArthritis Rheum. 2015;45(1):75–80.\n5. Choi HK, et al. Prevalence of the metabolic syndrome in individuals with\nhyperuricemia. Am J Med. 2007;120(5):442–7.\n6. Choi HK, Curhan G. Independent impact of gout on mortality and risk for\ncoronary heart disease. Circulation. 2007;116(8):894–900.\n7. Liu S-C, et al. Gout and Risk of Myocardial Infarction: A Systematic\nReview. PLoS ONE. 2015;10(7):e0134088.\n8. Choi HK, et al. Gout and the risk of type 2 diabetes among men with high\ncardiovascular risk profile. Rheumatology. 2008;47(10):1567–70.\n9. Roughley MJ, et al. Gout and risk of chronic kidney disease and\nnephrolithiasis: meta-analysis. Arthritis Res Ther. 2015;17(1).\n10. Kuo C-F, et al. Gout: an independent risk factor for all-cause and\ncardiovascular mortality. Rheumatology. 2010;49(1):141–6.\n11. Fisher MC, et al. Premature mortality gap in gout: a general\npopulation-based study. Ann Rheum Dis. 2017;76(7):1289–94.\nAbout XORTX Therapeutics Inc.\n\nXORTX is a pharmaceutical company with three clinically advanced products in\ndevelopment: 1) our lead XRx-026 program for the treatment of gout; 2) XRx-008\nprogram for ADPKD; and 3) XRx-101 for acute kidney and other acute organ\ninjury associated with respiratory virus infections. In addition, the Company\nis developing XRx-225, a pre-clinical stage program for Type 2 diabetic\nnephropathy, and the recently acquired VB4-P5 program, which is currently at\nthe pre-IND stage of development and targets both rare and prevalent forms of\nkidney disease. XORTX is working to advance products that target aberrant\npurine metabolism and xanthine oxidase to decrease or inhibit production of\nuric acid. At XORTX, we are dedicated to developing medications that improve\nthe quality of life and health of individuals with gout and other important\ndiseases.\n\nFor more information, please contact:\n\n Allen Davidoff, Co-CEO    Mika Grasso, Co-CEO  \n adavidoff@xortx.com       mgrasso@xortx.com    \n +1 403 455 7727           +1 949 244 6011      \n                                                \n\nForward-Looking Statements\n\nThis press release contains “forward-looking statements” within the\nmeaning of the safe harbor provisions of the U.S. Private Securities\nLitigation Reform Act of 1995, as well as “forward-looking information”\nwithin the meaning of applicable Canadian securities laws. Forward-looking\nstatements may be identified by the use of words such as “anticipate,”\n“believe,” “expect,” “estimate,” “plan,” “intend,”\n“will,” “designed to,” “enable,” “accelerate,” “extend,”\n“potential,” “looks forward,” and similar expressions, and include all\nstatements that are not statements of historical fact. These forward-looking\nstatements include, but are not limited to, statements regarding the\npreparation, timing, content and submission of the Company’s planned CTA to\nHealth Canada for the XRx-026 program; the design, initiation, conduct and\ncompletion of the planned two-part XRX-OXY-102 clinical study, including the\nCompany’s plan to conduct the first part of the study in Canada; the\nCompany’s expectation that conducting the first part of the study in Canada\nwill accelerate the delivery of clinical data in support of its planned NDA\nfiling with the FDA; the Company’s regulatory strategy in the United States,\nCanada and other jurisdictions, including the timing and content of its\nplanned regulatory submissions to the FDA and its intention to advance the\nXRx-026 program toward regulatory approval in Canada; the Company’s\nexpectations regarding the more efficient use of its capital, personnel and\ntime and the potential to accelerate the availability of XORLO™ to patients;\ninterest from, and the potential for arrangements with, commercialization\npartners; statements regarding the prevalence of hyperuricemia and gout and\nthe projected growth in the prevalence of gout, which are based on third-party\ndata; and the advancement of the Company’s XRx-026 program, its other\ndevelopment programs, and its strategy.\n\nForward-looking statements are based on the Company’s current expectations\nand assumptions and are subject to known and unknown risks, uncertainties, and\nother factors that could cause actual results, performance, or achievements to\ndiffer materially from those expressed or implied by such statements. Such\nrisks and uncertainties include, among others: the Company’s need for, and\nability to obtain, additional capital to fund its development programs and\noperations; the risk that the Company’s CTA submission to Health Canada is\ndelayed or, once submitted, is not accepted by Health Canada, is subject to\nobjection or to requests for additional information or data, or is otherwise\nnot permitted to proceed; the risk that the Company’s regulatory submissions\nto the FDA are delayed or not accepted, or that the planned XRX-OXY-102\nclinical study is placed on clinical hold or otherwise not permitted to\nproceed by the FDA; the Company’s ability to initiate, conduct, and complete\nthe planned XRX-OXY-102 clinical study, in Canada and elsewhere, on the\ntimelines currently anticipated, or at all, and the risk that the results of\nthat study are not positive, are not accepted by the FDA, or do not support an\nNDA submission; the risk that Health Canada or the FDA does not agree with the\nCompany’s proposed clinical development plan or regulatory pathway, or\nrequires additional studies or data; the Company’s reliance on third-party\ncontract research organizations and contract manufacturers; the risk that\ndiscussions with potential commercialization partners do not result in any\nagreement on acceptable terms, or at all; the risk that third-party data\nregarding the prevalence of hyperuricemia and gout, and projections of future\nprevalence, prove to be inaccurate; competition from existing and future\ntherapies for gout; the Company’s ability to advance, and obtain regulatory\napproval for, the XRx-026 program and its other product candidates on the\ntimelines currently anticipated, or at all; the evolving regulatory\nenvironment applicable to the Company’s business in the United States and\nCanada; the Company’s ability to maintain the listing of its common shares\non the Nasdaq Capital Market; and the Company’s ability to attract and\nretain qualified personnel.\n\nFor a more detailed discussion of these and other risks and uncertainties,\ninvestors should review the disclosures contained under the heading “Risk\nFactors” in the Company’s Annual Report on Form 20-F for the fiscal year\nended December 31, 2025, and in the Company’s subsequent Reports of Foreign\nPrivate Issuer on Form 6-K, each as filed with or furnished to the SEC and\navailable at www.sec.gov, as well as in the Company’s continuous disclosure\ndocuments filed with the Canadian securities regulatory authorities and\navailable at www.sedarplus.ca.\n\nThe forward-looking statements in this press release speak only as of the date\nhereof. Except as required by law, the Company undertakes no obligation to\nupdate or revise any forward-looking statement, whether as a result of new\ninformation, future events, or otherwise. Readers are cautioned not to place\nundue reliance on these forward-looking statements.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/9898c4f8-b373-438a-abfa-709c4372a061)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-08T20:00:00.22222557Z","server_sent_at_ms":1791489600222},"received_at":"2026-10-08T20:00:00.313Z","source_url":null},"analysis":{"id":"153184","press_release_id":"164770","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["CTA is planned, not filed or accepted -- timing and acceptance subject to regulatory risk","no partnership agreements signed despite disclosure of inquiries","company cites need for additional capital and Nasdaq listing maintenance as risk factors"],"eventType":"regulatory","narrative":"XORTX Therapeutics outlined its anticipated Clinical Trial Application to Health Canada for the XRx-026 gout program, featuring its proprietary oxypurinol formulation XORLO.\n\nThe CTA supports the planned two-part XRX-OXY-102 study, with part one to be run in Canada to accelerate clinical data delivery ahead of a planned NDA filing with the FDA.\n\nThe company also noted increased partnership inquiries but disclosed no agreements, and no trial has yet begun or filing been accepted.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Micro-cap biotech broadens regulatory strategy for gout asset with planned Health Canada CTA ahead of FDA NDA push."},"keyFigures":{"drugName":"XORLO (proprietary oxypurinol formulation, XRx-026 program)","phaseOfTrial":"planned two-part clinical study XRX-OXY-102","customDimensions":{"us_gout_prevalence":"9.2 million","febuxostat_peak_sales":">US$450 million","gout_growth_projection":"70% increase over next 25 years","us_hyperuricemia_prevalence":"approximately 44 million"}},"quotedText":"Advancing our Clinical Trial Application with Health Canada is expected to enable more efficient clinical plan execution and extends our regulatory strategy for XRx-026 globally","namedEntities":{"people":[{"name":"Dr. Allen Davidoff","role":"Co-Chief Executive Officer"},{"name":"Mika Grasso","role":"Co-Chief Executive Officer"}],"products":["XORLO","XRx-026","XRx-008","XRx-101","XRx-225","VB4-P5","oxypurinol"],"companies":[{"name":"XORTX Therapeutics Inc.","ticker":"XRTX","relationship":"filer"},{"name":"Health Canada","relationship":"regulator"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"}],"dollarAmounts":[{"amount":">US$450 million","context":"historical peak annual net sales of febuxostat, a competing xanthine oxidase inhibitor"}]},"materialImpact":{"score":2,"reasoning":"Announcement of a planned (not yet filed) Clinical Trial Application to Health Canada for the XRx-026 gout program, extending the regulatory strategy and supporting the planned XRX-OXY-102 study. It is a forward-looking strategy update, not an approval, data readout, or filed submission, so impact is modest for a micro-cap clinical-stage biotech."},"tickerRelevance":{"others":[],"primary":"XRTX"},"globalImportance":14,"audienceRelevance":10,"eventTypeSecondary":["clinical_trial"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"planned regulatory filing outline, no new data or approval","issuerAuthored":true}},"event_type":"regulatory","event_type_secondary":["clinical_trial"],"sentiment":"bullish","material_impact_score":2,"narrative":"XORTX Therapeutics outlined its anticipated Clinical Trial Application to Health Canada for the XRx-026 gout program, featuring its proprietary oxypurinol formulation XORLO.\n\nThe CTA supports the planned two-part XRX-OXY-102 study, with part one to be run in Canada to accelerate clinical data delivery ahead of a planned NDA filing with the FDA.\n\nThe company also noted increased partnership inquiries but disclosed no agreements, and no trial has yet begun or filing been accepted.","key_figures":{"drugName":"XORLO (proprietary oxypurinol formulation, XRx-026 program)","phaseOfTrial":"planned two-part clinical study XRX-OXY-102","customDimensions":{"us_gout_prevalence":"9.2 million","febuxostat_peak_sales":">US$450 million","gout_growth_projection":"70% increase over next 25 years","us_hyperuricemia_prevalence":"approximately 44 million"}},"named_entities":{"people":[{"name":"Dr. Allen Davidoff","role":"Co-Chief Executive Officer"},{"name":"Mika Grasso","role":"Co-Chief Executive Officer"}],"products":["XORLO","XRx-026","XRx-008","XRx-101","XRx-225","VB4-P5","oxypurinol"],"companies":[{"name":"XORTX Therapeutics Inc.","ticker":"XRTX","relationship":"filer"},{"name":"Health Canada","relationship":"regulator"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"}],"dollarAmounts":[{"amount":">US$450 million","context":"historical peak annual net sales of febuxostat, a competing xanthine oxidase inhibitor"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-08T20:00:06.526Z","global_importance":14,"audience_relevance":10,"importance_components":{"tickerTier":"micro-cap","eventGravity":"planned regulatory filing outline, no new data or approval","issuerAuthored":true}},"durationMs":6177,"modelName":"glm-5.3-flashx"}}